IQVIA (IQV) stock
Health Care · Life Sciences Tools & Services
IQVIA (IQV) is a Life Sciences Tools & Services company in the Health Care sector, headquartered in Durham, North Carolina. As of October 23, 2026, IQV closed at $279.36, a market capitalization of $45.98 billion, the 248th largest company in the S&P 500. The stock trades at 34.7x trailing earnings and 19.4x forward earnings.
- 1-year total return: +27.0% (dividends reinvested)
- 5-year return: +1.7% a year
- 52-week range: $154.50 – $282.98
- FI Handbook report card: B+ across 5 metrics
- 32nd largest of 60 Health Care stocks in the S&P 500
IQV price chart
1Y price change: +27.0% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| IQV | +4.3% | +23.9% | +27.0% | +15.0% | +1.7% | +14.2% | +15.1% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 2013.
IQV key statistics
- Market cap
- $46.0B
- #248 in S&P 500
- P/E (TTM)
- 34.7x
- Forward P/E
- 19.4x
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Free cash flow
- $2.2B
- Gross margin
- —
- Operating margin
- —
- Return on equity
- —
- Dividend yield
- None
- 52-week range
- $154.50 – $282.98
- Beta
- —
- Price / sales
- —
- EV / EBITDA
- —
- Debt / equity
- —
- Employees
- —
IQV report card
B+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth——
- Gross margin——
- Operating margin——
- FCF margin——
- Return on equity——
- Net debt / EBITDA0.0xA
- Forward P/E19.4xB
- PEG ratio1.0xA
- Shareholder yield2.7%C
- Share count change / yr-2.3%A
IQVIA financials
Revenue went from $6.8B in fiscal 2016 to $16.3B in fiscal 2025, growing 10.2% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8B | $9.7B | $10.4B | $11.1B | $11.4B | $13.9B | $14.4B | $15.0B | $15.4B | $16.3B |
| Gross profit | $3.6B | $5.1B | — | — | — | — | — | — | — | — |
| Operating income | $576.0M | $665.0M | $741.0M | $777.0M | $731.0M | $1.4B | $1.8B | $2.0B | $2.2B | $2.2B |
| Net income | $72.0M | $1.3B | $259.0M | $191.0M | $279.0M | $966.0M | $1.1B | $1.4B | $1.4B | $1.4B |
| EPS (diluted) | $0.47 | $5.74 | $1.24 | $0.96 | $1.43 | $4.95 | $5.72 | $7.29 | $7.49 | $7.84 |
| Free cash flow | $696.0M | $601.0M | $795.0M | $835.0M | $1.3B | $2.3B | $1.6B | $1.5B | $2.1B | $2.1B |
| Buybacks | $1.1B | $2.6B | $1.4B | $949.0M | $447.0M | $406.0M | $1.2B | $992.0M | $1.4B | $1.2B |
| Diluted shares | 152.0M | 222.6M | 208.2M | 199.6M | 195.0M | 195.0M | 190.6M | 186.3M | 183.4M | 173.5M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into IQV?
A reverse DCF asks what growth the current price requires. With an enterprise value of $46.0B and $2.2B of trailing free cash flow, IQVIA needs to grow free cash flow about 11.8% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 8.8% a year over the last five years.
P/E ratio history
Current 35.6x vs. median 33.0x (10th–90th percentile 22.1x–181.0x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
IQV analyst price targets
21 analysts' average 12-month target is $302.67 (+8% vs. $279.36). Targets range from $268.00 to $345.00. 90% rate it a buy.
IQV earnings
Next report: October 27, 2026. IQVIA has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $4.4B (+9% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 28, 2026 | $3.03 | $3.15 | +3.9% |
| May 5, 2026 | $2.82 | $2.90 | +3.0% |
| Feb 5, 2026 | $3.40 | $3.42 | +0.7% |
| Oct 28, 2025 | $2.98 | $3.00 | +0.8% |
| Jul 22, 2025 | $2.77 | $2.81 | +1.4% |
| May 6, 2025 | $2.63 | $2.70 | +2.6% |
| Feb 6, 2025 | $3.11 | $3.12 | +0.4% |
| Oct 31, 2024 | $2.81 | $2.84 | +1.0% |
Stocks like IQV
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 TMO Thermo Fisher Scientific | -0.40% | +18% | $249.1B | 35.5x | Compare |
 DHR Danaher | +0.33% | +4% | $162.0B | 38.2x | Compare |
 A Agilent Technologies | -0.47% | +18% | $48.8B | 34.1x | Compare |
 WAT Waters | -0.42% | +28% | $44.5B | 114.9x | Compare |
 ILMN Illumina | +0.01% | +170% | $40.7B | 50.3x | Compare |
 MTD Mettler-Toledo International, I | -0.85% | +16% | $33.5B | 37.6x | Compare |
 CRL Charles River Laboratories Inte | +1.68% | +81% | $16.6B | — | Compare |
 TECH Bio-Techne | -0.10% | +10% | $11.4B | 62.5x | Compare |
IQV news
- From Headwinds to Full Valuation: The Disciplined Exit of IQVIA Holdings (IQV) · Oct 23, 2026
- IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know · Oct 22, 2026
- IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? · Oct 20, 2026
- 1 Large-Cap Stock to Research Further and 2 We Avoid · Oct 19, 2026
- IQVIA Holdings (IQV) Gains as Improving Demand Environment and High Win Rates · Oct 15, 2026
IQV stock FAQ
What is IQV's market cap?
IQVIA's market capitalization is $45.98 billion as of October 23, 2026, ranking 248th in the S&P 500.
What is IQV's P/E ratio?
IQV trades at a trailing price-to-earnings ratio of 34.7x and a forward P/E of 19.4x. Its median P/E over the period we track is 33.0x.
Does IQV pay a dividend?
No. IQVIA does not currently pay a regular cash dividend.
How much has IQV stock returned?
Including reinvested dividends, IQV returned +27.0% over one year, +1.7% a year over five years, +14.2% a year over ten years through October 23, 2026.
Is IQV stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies IQVIA must grow free cash flow about 12% a year for the next decade. Its free cash flow grew 9% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the IQV price target?
21 analysts cover IQV with an average 12-month price target of $302.67, +8% from the current price. 90% of them rate it a buy.
When does IQV report earnings?
IQVIA is expected to report earnings on October 27, 2026. It has beaten EPS estimates 8 quarters in a row.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology